RAPT Therapeutics, Inc.
RAPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.33 | -0.02 |
| FCF Yield | -1.79% | -5.25% | -2.50% | -1.77% |
| EV / EBITDA | -34.07 | -10.14 | -107.61 | -7.84 |
| Quality | ||||
| ROIC | -12.53% | -11.66% | -10.63% | -28.02% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 0.64 | 3.05 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -10.14% | 78.44% | -402.56% | 40.82% |
| Safety | ||||
| Net Debt / EBITDA | 1.82 | 2.22 | 2.97 | 3.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,885.05 | 0.00 | 0.00 |